Global Custom Market Research Reports Provider Company

phone

Nuclear Factor Erythroid 2 Related Factor 2 (HEBP1 or Nuclear Factor Erythroid Derived 2 Like 2 or NFE2L2) - Pipeline Review, H2 2017

  • Published Date: 29 Dec 2017
  • Number of Pages: 110
  • Category: Healthcare and Medical
  • Country: Global
Nuclear Factor Erythroid 2 Related Factor 2 (HEBP1 or Nuclear Factor Erythroid Derived 2 Like 2 or NFE2L2) - Pipeline Review, H2 2017

Summary

Nuclear Factor Erythroid 2 Related Factor 2 (HEBP1 or Nuclear Factor Erythroid Derived 2 Like 2 or NFE2L2) - Nuclear factor (erythroid-derived 2)-like 2 or Nrf2 is a transcription factor encoded by the NFE2L2 gene. It binds to antioxidant response elements in the promoter regions of target genes. It is important for the coordinated up-regulation of genes in response to oxidative stress. It is involved in the transcriptional activation of genes of the beta-globin cluster by mediating enhancer activity of hypersensitive site 2 of the beta-globin locus control region.

Nuclear Factor Erythroid 2 Related Factor 2 (HEBP1 or Nuclear Factor Erythroid Derived 2 Like 2 or NFE2L2) pipeline Target constitutes close to 35 molecules. Out of which approximately 25 molecules are developed by companies and remaining by the universities/institutes. The molecules developed by companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 4, 2, 3, 15 and 1 respectively. Similarly, the universities portfolio in Preclinical and Discovery stages comprises 7 and 3 molecules, respectively. Report covers products from therapy areas Central Nervous System, Immunology, Oncology, Metabolic Disorders, Cardiovascular, Respiratory, Ophthalmology, Gastrointestinal, Toxicology, Genetic Disorders, Genito Urinary System And Sex Hormones, Infectious Disease and Musculoskeletal Disorders which include indications Inflammation, Multiple Sclerosis, Chronic Obstructive Pulmonary Disease (COPD), Diabetic Nephropathy, Psoriasis, Type 2 Diabetes, Amyotrophic Lateral Sclerosis, Cardiomyopathy, Diabetic Complications, Friedreich Ataxia, Parkinsons Disease, Pulmonary Arterial Hypertension, Systemic Sclerosis (Scleroderma), Type 1 Diabetes (Juvenile Diabetes), Age Related Macular Degeneration, AIDS Associated Dementia, Alport Syndrome, Alzheimers Disease, Aspiration Pneumonitis, Asthma, Atherosclerosis, Autism, Brain Ischemia, Breast Cancer, Cardiovascular Disease, Cerebral Vasospasm, Chagas Disease (American Trypanosomiasis), Chronic Kidney Disease (Chronic Renal Failure), Encephalomyelitis, Focal Segmental Glomerulosclerosis (FSGS), Huntington Disease, Idiopathic Pulmonary Fibrosis, Idiopathic Pulmonary Hypertension, Ischemia Reperfusion Injury, Ischemic Stroke, Medulloblastoma, Metastatic Breast Cancer, Metastatic Melanoma, Mitochondrial Diseases, Nephropathy, Neuro Muscular Disorders, Neuroblastoma, Neurodegenerative Diseases, Non Alcoholic Fatty Liver Disease (NAFLD), Non-Hodgkin Lymphoma, Non-Small Cell Lung Cancer, Osteoarthritis, Osteoporosis, Ovarian Cancer, Plaque Psoriasis (Psoriasis Vulgaris), Polycystic Kidney Disease, Post-Myocardial Infarction, Primary Progressive Multiple Sclerosis (PPMS), Prostate Cancer, Pulmonary Hypertension, Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome), Radiodermatitis, Relapsing Remitting Multiple Sclerosis (RRMS), Retinal Degeneration, Retinopathy, Subarachnoid Hemorrhage and Ulcerative Colitis.

The latest report Nuclear Factor Erythroid 2 Related Factor 2 - Pipeline Review, H2 2017, outlays comprehensive information on the Nuclear Factor Erythroid 2 Related Factor 2 (HEBP1 or Nuclear Factor Erythroid Derived 2 Like 2 or NFE2L2) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews key players involved in Nuclear Factor Erythroid 2 Related Factor 2 (HEBP1 or Nuclear Factor Erythroid Derived 2 Like 2 or NFE2L2) targeted therapeutics development with respective active and dormant or discontinued projects.

The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape for Nuclear Factor Erythroid 2 Related Factor 2 (HEBP1 or Nuclear Factor Erythroid Derived 2 Like 2 or NFE2L2)
- The report reviews Nuclear Factor Erythroid 2 Related Factor 2 (HEBP1 or Nuclear Factor Erythroid Derived 2 Like 2 or NFE2L2) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in Nuclear Factor Erythroid 2 Related Factor 2 (HEBP1 or Nuclear Factor Erythroid Derived 2 Like 2 or NFE2L2) targeted therapeutics and enlists all their major and minor projects
- The report assesses Nuclear Factor Erythroid 2 Related Factor 2 (HEBP1 or Nuclear Factor Erythroid Derived 2 Like 2 or NFE2L2) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to Nuclear Factor Erythroid 2 Related Factor 2 (HEBP1 or Nuclear Factor Erythroid Derived 2 Like 2 or NFE2L2) targeted therapeutics

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for Nuclear Factor Erythroid 2 Related Factor 2 (HEBP1 or Nuclear Factor Erythroid Derived 2 Like 2 or NFE2L2)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and its most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Nuclear Factor Erythroid 2 Related Factor 2 (HEBP1 or Nuclear Factor Erythroid Derived 2 Like 2 or NFE2L2) development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope
Publisher Name : Global Markets Direct
Table of Contents
List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Nuclear Factor Erythroid 2 Related Factor 2 (HEBP1 or Nuclear Factor Erythroid Derived 2 Like 2 or NFE2L2) - Overview
Nuclear Factor Erythroid 2 Related Factor 2 (HEBP1 or Nuclear Factor Erythroid Derived 2 Like 2 or NFE2L2) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Products under Development by Universities/Institutes
Nuclear Factor Erythroid 2 Related Factor 2 (HEBP1 or Nuclear Factor Erythroid Derived 2 Like 2 or NFE2L2) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Nuclear Factor Erythroid 2 Related Factor 2 (HEBP1 or Nuclear Factor Erythroid Derived 2 Like 2 or NFE2L2) - Companies Involved in Therapeutics Development
Arbor Pharmaceuticals LLC
Bayer AG
BioApex sro
Biogen Inc
C4X Discovery Holdings PLC
Catabasis Pharmaceuticals Inc
Daiichi Sankyo Co Ltd
Evgen Pharma Plc
Ixchel Pharma LLC
Jiangsu Hengrui Medicine Co Ltd
Mochida Pharmaceutical Co Ltd
Reata Pharmaceuticals Inc
Rigel Pharmaceuticals Inc
vTv Therapeutics Inc
Nuclear Factor Erythroid 2 Related Factor 2 (HEBP1 or Nuclear Factor Erythroid Derived 2 Like 2 or NFE2L2) - Drug Profiles
BA-1521 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
bardoxolone methyl - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CAT-4001 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
DH-404 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
dimethyl fumarate DR - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
IXC-103 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
LGM-2605 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
LH-503 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
LH-526 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
MG-132 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
MIND-4 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
monosodium luminol - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
nifurtimox - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
omaveloxolone - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
R-970 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
RS-9 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
RTI-79 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SFX-01 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SFX-02 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SFX-03 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Activate NF-E2 Related Factor 2 for Central Nervous System, Metabolic Disorders, Cardiovascular and Ophthalmology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Activate Nrf2 for Inflammation - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Activate Nrf2 for Inflammation - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Target NRF2 and BACH1 for Parkinsons Disease - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules 2 to Activate Nrf2 for Oncology and Inflammation - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Activate NRF-2 for COPD - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Activate Nrf2 for Oncology and Inflammation - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit GSK3B and Activate Nrf2 for Alzheimers Disease - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SUL-121 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
TBE-31 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
tepilamide fumarate - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
TFM-735 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
VCB-101 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
VCB-102 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
VEDA-1209 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Nuclear Factor Erythroid 2 Related Factor 2 (HEBP1 or Nuclear Factor Erythroid Derived 2 Like 2 or NFE2L2) - Dormant Products
Nuclear Factor Erythroid 2 Related Factor 2 (HEBP1 or Nuclear Factor Erythroid Derived 2 Like 2 or NFE2L2) - Discontinued Products
Nuclear Factor Erythroid 2 Related Factor 2 (HEBP1 or Nuclear Factor Erythroid Derived 2 Like 2 or NFE2L2) - Product Development Milestones
Featured News & Press Releases
Dec 11, 2017: Hardman Research: Funded to the end of Phase II trials
Dec 11, 2017: Reata Pharmaceuticals Presents Interim Phase 1b Data for Omaveloxolone in the Treatment of Unresectable or Metastatic Melanoma
Dec 08, 2017: Novel Compound Restores Immune Response In Patients With Melanoma
Nov 06, 2017: Kyowa Hakko Kirin Presented Results of Phase II Study of Bardoxolone Methyl in Japan at the ASN Kidney Week 2017
Nov 06, 2017: Reata Provides Update on Bardoxolone Methyl from the American Society of Nephrology Kidney Week Meeting
Nov 03, 2017: Reata Announces Primary Results from the Phase 2 CARDINAL Study of Bardoxolone in Alport Syndrome at the American Society of Nephrology Kidney Week 2017 Annual Meeting
Oct 23, 2017: Reata Announces First Patient Enrolled in Part 2 of MOXIe Study of Omaveloxolone for the Treatment of Friedreichs Ataxia
Oct 20, 2017: Reata Announces Late-Breaking Presentation of Primary Results From Phase 2 CARDINAL Study at the American Society of Nephrology Kidney Week 2017 Annual Meeting
Oct 04, 2017: Evgen Pharma: First European Patent Grant
Sep 13, 2017: Reata Pharmaceuticals, Inc. Receives Orphan Drug Designation for Omaveloxolone for the Treatment of Malignant Melanoma
Aug 14, 2017: FDA Confirms That Use of mFARS as Primary Endpoint in Part 2 of the MOXIe Trial Can Support Approval of Omaveloxolone in Friedreichs Ataxia
Aug 07, 2017: Reata Announces First Patient Enrolled in Phase 3 CARDINAL Trial of Bardoxolone Methyl in the Treatment of Chronic Kidney Disease Due to Alport Syndrome
Aug 02, 2017: Evgen Pharma: SFX-01 data published in Peer Reviewed Journal
Aug 01, 2017: Department Of Defense Report Shows Bach Pharma Drug GVT Reverses Brain Dysfunction
Jul 24, 2017: Reatas Bardoxolone Methyl Demonstrated Improved Kidney Function in Patients With Alport Syndrome in Ongoing Phase 2 Portion of Phase 2/3 Cardinal Study
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List Of Tables


Number of Products under Development by Stage of Development, H2 2017
Number of Products under Development by Therapy Areas, H2 2017
Number of Products under Development by Indications, H2 2017
Number of Products under Development by Indications, H2 2017 (Contd..1), H2 2017
Number of Products under Development by Indications, H2 2017 (Contd..2), H2 2017
Number of Products under Development by Indications, H2 2017 (Contd..3), H2 2017
Number of Products under Development by Companies, H2 2017
Products under Development by Companies, H2 2017
Products under Development by Companies, H2 2017 (Contd..1), H2 2017
Products under Development by Companies, H2 2017 (Contd..2), H2 2017
Products under Development by Companies, H2 2017 (Contd..3), H2 2017
Number of Products under Investigation by Universities/Institutes, H2 2017
Products under Investigation by Universities/Institutes, H2 2017
Products under Investigation by Universities/Institutes, H2 2017 (Contd..1), H2 2017
Number of Products by Stage and Mechanism of Actions, H2 2017
Number of Products by Stage and Route of Administration, H2 2017
Number of Products by Stage and Molecule Type, H2 2017
Pipeline by Arbor Pharmaceuticals LLC, H2 2017
Pipeline by Bayer AG, H2 2017
Pipeline by BioApex sro, H2 2017
Pipeline by Biogen Inc, H2 2017
Pipeline by C4X Discovery Holdings PLC, H2 2017
Pipeline by Catabasis Pharmaceuticals Inc, H2 2017
Pipeline by Daiichi Sankyo Co Ltd, H2 2017
Pipeline by Evgen Pharma Plc, H2 2017
Pipeline by Ixchel Pharma LLC, H2 2017
Pipeline by Jiangsu Hengrui Medicine Co Ltd, H2 2017
Pipeline by Mochida Pharmaceutical Co Ltd, H2 2017
Pipeline by Reata Pharmaceuticals Inc, H2 2017
Pipeline by Rigel Pharmaceuticals Inc, H2 2017
Pipeline by vTv Therapeutics Inc, H2 2017
Dormant Products, H2 2017
Dormant Products, H2 2017 (Contd..1), H2 2017
Dormant Products, H2 2017 (Contd..2), H2 2017
Discontinued Products, H2 2017

List Of Figures


Number of Products under Development by Stage of Development, H2 2017
Number of Products under Development by Therapy Areas, H2 2017
Number of Products under Development by Top 10 Indications, H2 2017
Number of Products by Mechanism of Actions, H2 2017
Number of Products by Stage and Mechanism of Actions, H2 2017
Number of Products by Routes of Administration, H2 2017
Number of Products by Stage and Routes of Administration, H2 2017
Number of Products by Molecule Types, H2 2017
Number of Products by Stage and Molecule Types, H2 2017

Inhibitor of Nuclear Factor Kappa B Kinase Subunit Beta (Nuclear Factor NF Kappa B Inhibitor Kinase Beta or I Kappa B Kinase 2 or IKBKB or EC 2.7.11.10) - Pipeline

View Report

Societatea Nationala Nuclearelectrica SA (SNN) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the companys businesses and operations. The profile has been compiled

View Report

Retinoic Acid Receptor Gamma (RAR Gamma or Nuclear Receptor Subfamily 1 Group B Member 3 or NR1B3 or RARG) - Pipeline Review, H2 2018 According to the recently published report Retinoic

View Report
There is no reviews available for this report

Select License Type

Delivery Details

Delivery Details : Electronic files (PDF) of market research reports will dispatched within 12 to 24 hours. (Mon-Fri IST)

Customized Report

If a particular report is not as per your requirement you can ‎choose "Customized Report". To visit click on -

Custom Research Reports